Molecular and Treatment Characteristics of SMARCB1 or SMARCA4-Deficient Undifferentiated Tumor: Retrospective Case Series
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
SMARCB1 or SMARCA4-deficient sinonasal carcinoma or thoracic undifferentiated tumor has aggressive nature with a poor prognosis. Patients with this disease were diagnosed by immunohistochemistry or next-generation sequencing. Those who were able to receive a surgery tended to be cured, while the others treated with chemotherapy, radiation therapy, or immune checkpoint inhibitor were often insensitive to these therapies. However, one having CD274 (PD-L1) amplification showed the response to immune checkpoint inhibitor and a good prognosis. We believed that this report could provide promising information for determining the optimal treatment option.
Abstract
SMARCB1 or SMARCA4-deficient sinonasal carcinoma or thoracic undifferentiated tumor has aggressive nature with a poor prognosis. Patients with this disease were diagnosed by immunohistochemistry or next-generation sequencing. Those who were able to receive a surgery tended to be cured, while the others treated with chemotherapy, radiation therapy, or immune checkpoint inhibitor were often insensitive to these therapies. However, one having CD274 (PD-L1) amplification showed the response to immune checkpoint inhibitor and a good prognosis. We believed that this report could provide promising information for determining the optimal treatment option.
참고문헌 (15)
- Mittal P, "The SWI", SNF complex in cancer : biology, biomarkers and therapy, 2020, pp.17, 435~448
- Agaimy A, "SMARCB1(INI-1)-deficient sinonasal carcinoma : a series of 39 cases expanding the morphologic and clinicopathologic spectrum of a recently described entity", Am J Surg Pathol, 41, pp.458~471 (2017)
- Haberecker M, "Molecular and immunophenotypic characterization of SMARCB1(INI1)-deficient intrathoracic neoplasms", Mod Pathol, 35, pp.1860~1869 (2022)
- Contrera KJ, "Impact of clinical factors and treatments on SMARCB1(INI-1)-deficient sinonasal carcinoma", Otolaryngol Head Neck Surg, 169, pp.435~440 (2023)
- Lee VH, "SMARCB1(INI-1)-deficient sinonasal carcinoma : a systematic review and pooled analysis of treatment outcomes", Cancers(Basel), 14, pp.3285~ (2022)
- Agaimy A, "SMARCA4-deficient sinonasal carcinoma : a series of 10 cases expanding the genetic spectrum of SWI", SNF-driven sinonasal malignancies, 2020, pp.44, 703~710
- Wang R, "Clinical diagnosis and treatment analyses on SMARCB1(integrase interactor 1)-deficient sinonasal carcinoma : case series with systematic review of the literature", World Neurosurg, 161, pp.e229~e243 (2022)
- Thawani R, "The contemporary management of cancers of the sinonasal tract in adults", CA Cancer J Clin, 73, pp.72~112 (2023)
- Nambirajan A, "Recent updates in thoracic SMARCA4-deficient undifferentiated tumor", Semin Diagn Pathol, 38, pp.83~89 (2021)
- Bell EH, "SMARCA4", BRG1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non-small cell lung cancer, 2016, pp.22, 2396~2404
- Takada K, "Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1 : a case report", Thorac Cancer, 10, pp.2312~2315 (2019)
- Shi L, "Case report : a rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure", Front Oncol, 12, pp.1020875~ (2022)
- Henon C, "Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor", Ann Oncol, 30, pp.1401~1403 (2019)
- George J, "Genomic amplification of CD274(PD-L1)in small-cell lung cancer", Clin Cancer Res, 23, pp.1220~1226 (2017)
- Inoue Y, "CD274 (PD-L1) genomic change: another marker for small cell lung cancer?", Transl Cancer Res, 6(Suppl 1), pp.S33~S35 (2017)